.
.
.
.
Coronavirus

Storage challenges could hamper distribution of Pfizer, Moderna COVID-19 vaccines

Published: Updated:

Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, on Wednesday said it would be challenging to distribute vaccines that use messenger RNA based technology in developing countries, owing to their cold storage requirements.

The comments come days after Pfizer Inc said its experimental COVID-19 vaccine is more than 90 percent effective based on initial trial results and that it expects to file for US emergency authorization this month.

Visit our dedicated coronavirus site here for all the latest updates.

The vaccine candidate uses synthetic messenger RNA to activate the immune system against the virus and needs to be kept at minus 70 degrees Celsius (-94 F) or below.

“It does have cold-chain challenges as it were. In a country like the UK and the US we can address them and it still would be challenging. But, probably much more challenging in countries in the developing world,” Fauci said at the Financial Times’ global pharmaceutical and biotechnology conference.

Moderna Inc’s experimental vaccine, which is on track to report early data from a late-stage trial later this month, also uses mRNA technology and needs to be stored at minus 20 degrees Celsius (-4 F).

“That’s the reason why when we put together our plan ... we want to have a diversity of what we call vaccine platforms. It is not just mRNA ... there are three separate platforms that are being looked at in the US,” Fauci said.

Read More:

Coronavirus: Brazil’s health regulator allows resumption of Chinese vaccine trial

Coronavirus: Spain demands negative PCR for travelers from high risk countries

Coronavirus: EU seeks powers to stress test governments’ pandemic plans